Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00246519 · ClinicalTrials.gov registry record · Phase 4
Pharmacogenomic Evaluation of Antihypertensive Responses
A Phase 4 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,701
- Enrollment target
NCT00246519 is a Phase 4 study that has completed, run by University of Florida. The registered enrollment target is 1,701 participants.
The verdict
NCT00246519, a Phase 4 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,701 participants
- Enrollment target
Study Summary
There are many medications available for the treatment of high blood pressure (hypertension), but finding the right one for a specific patient can be challenging. In fact, it is estimated that only 34% of people with hypertension have their blood pressure under control. The hypothesis is that genetic differences between individuals influence their response to antihypertensive medications. This study is aimed at determining the genetic factors that may influence a person's response to either a beta-blocker or a thiazide diuretic. The hope is that through this research, we may someday be able to use an individual's genetic information to guide the selection of their blood pressure medicine, leading to better control of blood pressure, and less need for the current trial and error process.
Interventions
- DRUG Atenolol
- DRUG Hydrochlorothiazide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,701 participants |
| Start Date | 2005-10 |
| Est. Completion | 2010-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00246519
The ClinicalTrials.gov registry entry for NCT00246519 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,701 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atenolol is the first listed.
NCT00246519 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00246519 about?
NCT00246519 is a clinical study titled "Pharmacogenomic Evaluation of Antihypertensive Responses". There are many medications available for the treatment of high blood pressure (hypertension), but finding the right one for a specific patient can be challenging. In fact, it is estimated that only 34% of people with hypertension have their blood pressure under control. The hypothesis is that geneti...
What is the current status of trial NCT00246519?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,701 participants. The study started on 2005-10. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00246519?
The interventions under investigation include: Atenolol (DRUG), Hydrochlorothiazide (DRUG).
Who is sponsoring clinical trial NCT00246519?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.